Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging

Timothy M. Bateman

Status and phase

Completed

Phase 4

Conditions

Coronary Artery Disease

Treatments

Drug: Regadenoson

Study type

Interventional

Funder types

Other

Identifiers

NCT02115308

Astellas CMR Tagging

Details and patient eligibility

About

The purpose of this study is to measure the changes in cardiac function during a Lexiscan pharmacologic stress test using cardiac magnetic resonance imaging test.

Enrollment

40 patients

Sex

All

Ages

19 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Myocardial rest/regadenoson stress perfusion PET study within 60 days
Normal rest LVEF (greater than or equal to 50%)
No change in symptoms or treatment between the PET and the MRI study
Willing to consent to the study
Male or female who is either post-menopausal, surgically sterile, or if has a childbearing potential, a negative pregnancy test within 2 days prior to the MRI study.

Exclusion criteria

Renal dysfunction (estimated glomerular filtration rate < 60 mL/min/1.73m2) within 6 months
Metallic implants, pacemaker, blood vessel clip (contra-indicated for MRI)
Patient size exceeds MRI bore/table limits: (Max body diameter > 60 cm, weight > 136 kg)
History of gadolinium contrast allergy or intolerance
Second or third degree AV block
Sinus node dysfunction
Acute myocardial infarction (past 3 months)
Actively wheezing or with acute asthma or bronchospastic attacks requiring changes in therapy within the past 30 days
Patients that have experienced a previous hypersensitivity reaction thought to be related to regadenoson